Hyphens Pharma International

Broker's Calls

Analysts like Hyphens Pharma as FY2023 net profit come in above expectations

CGS International and PhillipCapital have kept their 'add' and 'buy' calls. They both have target prices of 35 cents on the stock.

Broker's Calls

CGS-CIMB maintains ‘add’ on Hyphens Pharma at lowered target price

Hyphens' gross profit margin showed a 4.8% y-o-y decline to 35.4% in 3QFY2023, which it attributes to inflationary cost pressures.

Results

Hyphens Pharma earnings down 47.2% y-o-y in 3QFY2023

Hyphen Pharma's 3QFY2023 earnings of $2.1 million shrank from $4.0 million in the same period last year.
Riverstone focuses on cleanrooms; Hyphens Pharma rides dual growth - THE EDGE SINGAPORE

Billion Dollar Club 2023

Riverstone focuses on cleanrooms; Hyphens Pharma rides dual growth

Riverstone cautions that the market for healthcare gloves might see consolidation in the coming years because of overcapacity.

Company in the news

Hyphens Pharma to acquire remaining 58% of shares in Ardence Pharma, making it a wholly-owned subsidiary

Hyphens Pharma sees the acquisition as a way to strengthen its Malaysian presence, first tranche worth $1.86 million.

Results

Hyphens Pharma reports two times surge in 2HFY2022 earnings of $5.2 mil

A first and final dividend of 1.11 cents has been proposed for the period, up from FY2021’s dividend of 0.67 cents.

Company in the news

Hyphens Pharma licenses topical drug for acne across all Southeast Asia

Hyphens Pharma called the drug a “game-changer” for acne sufferers as it is so far the only topical cream to treat hormonal acne.
After record 3QFY2022, CGS-CIMB lifts TP, EPS and dividend forecasts on Hyphens Pharma - THE EDGE SINGAPORE

Broker's Calls

After record 3QFY2022, CGS-CIMB lifts TP, EPS and dividend forecasts on Hyphens Pharma

Hyphens Pharma reported an almost threefold y-o-y jump in its 3QFY2022 profit after tax to $4.0 million.

Broker's Calls

'Add' Hyphens Pharma as it moves on to its next phase of growth

CGS-CIMB Research is betting on Hyphens Pharma's next phase of growth.
×